Drug
LN 145
LN 145: highest development phase Phase 2, developed by Iovance Biotherapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| LN-145 NCT07288073 | Phase 2 | Cutaneous Squamous Cell Carcinoma |
| LN-145 NCT04614103 | Phase 2 | Metastatic Non Small Cell Lung Cancer |
| LN-145 NCT03108495 | Phase 2 | Cervical Carcinoma |
| LN-145 NCT03083873 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
Latest
No recent events.
Follow LN 145 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.